
Leukemia
Latest News
Video Series

Latest Videos
Shorts










Podcasts
More News

A clinical trial will test zanubrutinib plus sonrotoclax as a fixed-duration, chemotherapy-free treatment for hairy cell leukemia, aiming for undetectable disease.

An expert discusses infection risks after treatment, what follow-up care looks like and why patients with a rare cancer should ask questions, seek expert opinions and find community.

Dr. Robert J. Kreitman explains how an experimental CAR T-cell therapy may help patients with relapsed hairy cell leukemia achieve lasting remissions.

Dr. Jacqueline Barrientos discussed how collaboration, individualized treatment and patient advocacy helped a 72-year-old man achieve leukemia remission and receive a kidney transplant.

Diagnosed with leukemia at 8 years old, Harper feared that losing her hair would change who she was. She reflects on body image, confidence and finding a sense of herself during cancer treatment.

Six years after a B-cell ALL diagnosis at 21, William Yank shares how his view of therapy changed and why he is still working on his mental health.

Replacing two cycles of intensive chemotherapy with Blincyto raised four-year event-free survival to 83% from 70.3% in children with high-risk B-cell ALL, with far fewer infections.

Six Years After Leukemia, He Is Rebuilding the Life Cancer Changed at 21
After two relapses, CAR-T cell therapy, immunotherapy and a stem cell transplant, William Yank's cancer is in remission, where he navigates a new reality shaped by infertility, mental health challenges and a changed sense of self.

After two relapses of acute lymphoblastic leukemia, Hannah Koepsell received CAR-T cell therapy. A pediatric oncologist explains why leukemia can return after treatment and how researchers are working to make CAR-T responses last longer.

See 5 years of FDA leukemia approvals for CLL, AML and CML — new drugs, new drug classes, and how many patients they've actually helped.

Hannah was 11 when she was diagnosed with acute lymphoblastic leukemia (ALL). Four years, two relapses and a 53-day hospital stay later, she is back in school.

In a new video Q&A with CURE, Dr. Silverman answers the most searched childhood leukemia questions.

Nicole Schulz was 14 when she received an AML diagnosis. She shares what carried her through two transplants and 11 months in the hospital.

FDA approved Cavhanza, a new nilotinib formulation for adults with Ph+ CML that may offer more flexible dosing and easier administration.

FDA approves oral Inqovi plus Venclexta for newly diagnosed AML in older adults or those with comorbidities, expanding non-intensive options.



























